Fig 1.
Flow chart illustrating study flow and patient selection.
Table 1.
Associations between presence of CTCs, patient characteristics and clinicopathological characteristics of the primary tumor.
Fig 2.
The distribution of samples (n = 642) according to CTC status and the highest HER2 staining intensity of CTCs in the samples.
Table 2.
Associations between presence of HER2-positive CTCs, patient characteristics and clinicopathological characteristics of the primary tumor.
Table 3.
Results of a multivariate logistic regression model with presence of HER-positive CTCs (yes/no) as binary response variable (n = 248 patients; 10 patients were excluded from the multivariate analysis because of missing values).
Fig 3.
The prevalence of HER2-positive CTCs (i.e., CTCs with strong HER2 staining) in relation to the number of CTCs detected in the blood samples (n = 258).
Fig 4.
The frequency and percentage (out of 258 CTC-positive samples) of samples with selected characteristics regarding the HER2 status of CTCs.
Table 4.
Between-sample and within-sample variability in the HER2 status of CTCs in patients with early HER2-positive breast cancer.